New York, 14 May 2019 – A team from Hogan Lovells has advised Medicines Development for Global Health (MDGH) in the sale of its Priority Review Voucher (PRV).
The PRV was awarded to MDGH in June 2018 by the U.S. Food & Drug Administration (FDA) following the FDA's approval of moxidectin (in patients aged 12 and older ), an oral treatment for river blindness (onchocerciasis), a debilitating disease affecting 20 million people, primarily in low-income countries. The Global Health Investment Fund (GHIF) provided $13 million since 2015 to support MDGH's efforts to complete clinical studies, manufacture moxidectin and conduct the FDA registration process. As a result of the transaction, significant proceeds will go towards additional research on moxidectin as well as its deployment in key underserved markets, where nearly 200 million individuals are at risk for river blindness.
MDGH was the first non-profit company to be awarded a priority review voucher by the FDA, and moxidectin is the first new FDA-approved treatment for river blindness in the last 20 years. Hogan Lovells also assisted MDGH in its efforts to obtain approval of moxidectin and qualify for the PRV.
The Hogan Lovells team advising MDGH was led by partners Adam Golden and Robert Church and senior associate Erin Howell.
About Hogan Lovells
Hogan Lovells is a leading global legal practice providing business-oriented legal advice and high-quality service across its exceptional breadth of practices to clients around the world.
"Hogan Lovells" or the "firm" is an international legal practice that includes Hogan Lovells US LLP and Hogan Lovells International LLP.